BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M. Surgical Treatments of Hepatobiliary Cancers. Hepatology 2021;73 Suppl 1:128-36. [PMID: 32438491 DOI: 10.1002/hep.31325] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 42.0] [Reference Citation Analysis]
Number Citing Articles
1 Song C, Zhang J, Wen R, Li Q, Zhou J, Xiaoli Liu, Wu Z, Lv Y, Wu R. Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles. Mater Today Bio 2022;16:100350. [PMID: 35856043 DOI: 10.1016/j.mtbio.2022.100350] [Reference Citation Analysis]
2 Luo D, Wang Y, Zhang M, Li H, Zhao D, Li H, Chen X, Jin C, Han B. SOCS5 knockdown suppresses metastasis of hepatocellular carcinoma by ameliorating HIF-1α-dependent mitochondrial damage. Cell Death Dis 2022;13:918. [PMID: 36319626 DOI: 10.1038/s41419-022-05361-z] [Reference Citation Analysis]
3 Xu J, Zhang L, Li N, Dai J, Zhang R, Yao F, Zhou S, Wu Z, Zhou H, Zhou L, Li Q, Wang X, Liu C. Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215970] [Reference Citation Analysis]
4 Lin X, Luo L, Zou Y, Chen J. Cancer stemness-associated LINC02475 serves as a novel biomarker for diagnosis and prognosis prediction of hepatocellular carcinoma. Front Genet 2022;13:991936. [DOI: 10.3389/fgene.2022.991936] [Reference Citation Analysis]
5 Gan X, Ding D, Wang M, Yang Y, Sun D, Li W, Ding W, Yang F, Zhou W, Yuan S. DANCR deletion retards the initiation and progression of hepatocellular carcinoma based on gene knockout and patient-derived xenograft in situ hepatoma mice model. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215930] [Reference Citation Analysis]
6 Xu W, Li B, Yang Z, Li J, Liu F, Liu Y. Rethinking Liver Fibrosis Staging in Patients with Hepatocellular Carcinoma: New Insights from a Large Two-Center Cohort Study. J Hepatocell Carcinoma 2022;9:751-81. [PMID: 35983561 DOI: 10.2147/JHC.S372577] [Reference Citation Analysis]
7 Lin ZF, Qin LX, Chen JH. Biomarkers for response to immunotherapy in hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00188-6. [PMID: 35973935 DOI: 10.1016/j.hbpd.2022.08.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu W, Song K, Zheng W, Huo L, Zhang S, Xu X, Wang P, Jia N. Hepatobiliary Phase Features of Preoperative Gadobenate-Enhanced MR can Predict Early Recurrence of Hepatocellular Carcinoma in Patients Who Underwent Anatomical Hepatectomy. Front Oncol 2022;12:862967. [DOI: 10.3389/fonc.2022.862967] [Reference Citation Analysis]
9 Li R, Zhao W, Liang R, Jin C, Xiong H. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Front Mol Biosci 2022;9:917839. [DOI: 10.3389/fmolb.2022.917839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cadamuro M, Romanzi A, Guido M, Sarcognato S, Cillo U, Gringeri E, Zanus G, Strazzabosco M, Simioni P, Villa E, Fabris L. Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. JPM 2022;12:1086. [DOI: 10.3390/jpm12071086] [Reference Citation Analysis]
11 Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-radosavljevic M. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. Cancers 2022;14:3093. [DOI: 10.3390/cancers14133093] [Reference Citation Analysis]
12 Xu MH, Xu B, Zhou CH, Xue Z, Chen ZS, Xu WX, Huang C, Zhu XD, Zhou J, Fan J, Sun HC, Shen YH. An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B-C in patients with huge hepatocellular carcinoma: a multi-institutional study. World J Surg Oncol 2022;20:206. [PMID: 35710377 DOI: 10.1186/s12957-022-02672-5] [Reference Citation Analysis]
13 Xu X, Ding P, Shi L, Wu G, Ma X. LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression. BMC Cancer 2022;22:630. [PMID: 35676659 DOI: 10.1186/s12885-022-09680-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Liu JP, Lerut J, Yang Z, Li ZK, Zheng SS. Three-dimensional modeling in complex liver surgery and liver transplantation. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00130-8. [PMID: 35701284 DOI: 10.1016/j.hbpd.2022.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang H, Yu L, Cui Y, Huang J, Shi Z. G Protein Subunit Gamma 5 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/1313359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cao P, Hong H, Yu Z, Chen G, Qi S. A Novel Clinically Prognostic Stratification Based on Prognostic Nutritional Index Status and Histological Grade in Patients With Gallbladder Cancer After Radical Surgery. Front Nutr 2022;9:850971. [DOI: 10.3389/fnut.2022.850971] [Reference Citation Analysis]
17 Xu W, Wang Y, Yang Z, Li J, Li R, Liu F. New Insights Into a Classification-Based Microvascular Invasion Prediction Model in Hepatocellular Carcinoma: A Multicenter Study. Front Oncol 2022;12:796311. [PMID: 35433417 DOI: 10.3389/fonc.2022.796311] [Reference Citation Analysis]
18 Wang N, Huang A, Kuang B, Xiao Y, Xiao Y, Ma H. Progress in Radiotherapy for Cholangiocarcinoma. Front Oncol 2022;12:868034. [DOI: 10.3389/fonc.2022.868034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Chen X, Wang Z, Zhao X, Zhang L, Zhou L, Li X, Ge C, Zhao F, Chen T, Xie H, Cui Y, Tian H, Li H, Yao M, Li J. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. Oncogene 2022. [PMID: 35314791 DOI: 10.1038/s41388-022-02273-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wang L, Liang L, Shi S, Wang C. Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer. Appl Bionics Biomech 2022;2022:2756459. [PMID: 35242218 DOI: 10.1155/2022/2756459] [Reference Citation Analysis]
21 Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Takahashi K, Gosho M, Kim J, Shimomura O, Miyazaki Y, Furuya K, Akashi Y, Enomoto T, Hashimoto S, Oda T. Prediction of Posthepatectomy Liver Failure with a Combination of Albumin-Bilirubin Score and Liver Resection Percentage. J Am Coll Surg 2022;234:155-65. [PMID: 35213436 DOI: 10.1097/XCS.0000000000000027] [Reference Citation Analysis]
23 Li J, Tian X, Nie Y, He Y, Wu W, Lei X, Zhang T, Wang Y, Mao Z, Zhang H, Zhang X, Song W. BTBD10 is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:762541. [PMID: 35059434 DOI: 10.3389/fmolb.2021.762541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Pant K, Gradilone SA. Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment. Technol Cancer Res Treat 2022;21:15330338221097203. [PMID: 35546130 DOI: 10.1177/15330338221097203] [Reference Citation Analysis]
25 Yang X, Liao HY, Zhang HH. Roles of MET in human cancer. Clin Chim Acta 2021;525:69-83. [PMID: 34951962 DOI: 10.1016/j.cca.2021.12.017] [Reference Citation Analysis]
26 Zhang T, Zhang S, Jin C, Lin Z, Deng T, Xie X, Deng L, Li X, Ma J, Ding X, Liu Y, Shan Y, Yu Z, Wang Y, Chen G, Li J. A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma. Front Cell Infect Microbiol 2021;11:751795. [PMID: 34888258 DOI: 10.3389/fcimb.2021.751795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
27 Ye D, Liu Y, Li G, Sun B, Peng J, Xu Q. A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients. Front Oncol 2021;11:766072. [PMID: 34868990 DOI: 10.3389/fonc.2021.766072] [Reference Citation Analysis]
28 Chen Z, Ju W, Chen C, Wang T, Yu J, Hong X, Dong Y, Chen M, He X. Application of various surgical techniques in liver transplantation: a retrospective study. Ann Transl Med 2021;9:1367. [PMID: 34733919 DOI: 10.21037/atm-21-1945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Wang X, Gu Y, Li Q, Xu Y, Shi Y, Wang Z, Xia M, Li J, Wang D. Synergistic chemo-photothermal cancer therapy of pH-responsive polymeric nanoparticles loaded IR825 and DTX with charge-reversal property. Colloids Surf B Biointerfaces 2021;209:112164. [PMID: 34735859 DOI: 10.1016/j.colsurfb.2021.112164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
30 Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:7977-87. [PMID: 34605616 DOI: 10.1002/cam4.4312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Xue C, Gu X, Li L. Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma. Cancer Cell Int 2021;21:471. [PMID: 34488768 DOI: 10.1186/s12935-021-02183-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Kuipers H, Hoogwater FJ, Holtman GA, van der Hoorn A, de Boer MT, de Haas RJ. Clinical value of diffusion-weighted MRI for differentiation between benign and malignant gallbladder disease: a systematic review and meta-analysis. Acta Radiol 2021;62:987-96. [PMID: 32830511 DOI: 10.1177/0284185120950115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
34 Lambrecht J, Porsch-Özçürümez M, Best J, Jost-Brinkmann F, Roderburg C, Demir M, Tacke F, Mohr R. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. J Clin Med 2021;10:3392. [PMID: 34362181 DOI: 10.3390/jcm10153392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Li T, Xu W, Liu C, He J, Wang Q, Zhang D, Sui K, Zhang Z, Sun H, Yang K, Tan L, Shao H. Anticancer Effect of Biodegradable Magnesium on Hepatobiliary Carcinoma: An In Vitro and In Vivo Study. ACS Biomater Sci Eng 2021;7:2774-82. [PMID: 34030441 DOI: 10.1021/acsbiomaterials.1c00288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Yin Y, Cheng JW, Chen FY, Chen XX, Zhang X, Huang A, Guo DZ, Wang YP, Cao Y, Fan J, Zhou J, Yang XR. A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma. Ann Transl Med 2021;9:774. [PMID: 34268387 DOI: 10.21037/atm-20-7842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Xin Y, Yang Y, Liu N, Chen Y, Wang Y, Zhang X, Li X, Zhou X. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol 2021;12:735-50. [PMID: 34012662 DOI: 10.21037/jgo-20-342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Shi Q, Meng Z, Tian XX, Wang YF, Wang WH. Identification and validation of a hub gene prognostic index for hepatocellular carcinoma. Future Oncol 2021;17:2193-208. [PMID: 33620260 DOI: 10.2217/fon-2020-1112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. Int J Mol Sci 2021;22:1492. [PMID: 33540837 DOI: 10.3390/ijms22031492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
40 Zheng Q, Fu Q, Xu J, Gu X, Zhou H, Zhi C. Transcription factor E2F4 is an indicator of poor prognosis and is related to immune infiltration in hepatocellular carcinoma. J Cancer 2021;12:1792-803. [PMID: 33613768 DOI: 10.7150/jca.51616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
41 Li J, Zhang S, Jin C, Lin Z, Xie X, Deng L, Wang M, Ma J, Li X, Ding X, Liu Y, Wang Y, Chen G. Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma. SSRN Journal. [DOI: 10.2139/ssrn.3759622] [Reference Citation Analysis]
42 Gao S, Chen T, Li L, Liu X, Liu Y, Zhao J, Lu Q, Zeng Z, Xu Q, Huang D, Tu K. Hypoxia-Inducible Ubiquitin Specific Peptidase 13 Contributes to Tumor Growth and Metastasis via Enhancing the Toll-Like Receptor 4/Myeloid Differentiation Primary Response Gene 88/Nuclear Factor-κB Pathway in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:587389. [PMID: 33195243 DOI: 10.3389/fcell.2020.587389] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
43 Lixin S, Wei S, Haibin S, Qingfu L, Tiemin P. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma. Mol Carcinog 2020;59:1371-81. [PMID: 33052627 DOI: 10.1002/mc.23262] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
44 Zhou Z, Zhou Z, Huang Z, He S, Chen S. Histone-fold centromere protein W (CENP-W) is associated with the biological behavior of hepatocellular carcinoma cells. Bioengineered 2020;11:729-42. [PMID: 32635817 DOI: 10.1080/21655979.2020.1787776] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
45 Guo X, Chen J, Zeng B, Lai J, Lin C, Lai M. Ultrasound-mediated delivery of RGD-conjugated nanobubbles loaded with fingolimod and superparamagnetic iron oxide nanoparticles: targeting hepatocellular carcinoma and enhancing magnetic resonance imaging. RSC Adv 2020;10:39348-58. [DOI: 10.1039/d0ra06415g] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]